Hematology & Transfusion International Journal最新文献

筛选
英文 中文
Pattern of hematological disorders on bone marrow examination: a tertiary care hospital experience 骨髓检查的血液病模式:三级医院的经验
Hematology & Transfusion International Journal Pub Date : 2021-12-09 DOI: 10.15406/htij.2021.09.00267
N. Fareed, T. Mehmood, M. Quraishy, Ghulam Fatima
{"title":"Pattern of hematological disorders on bone marrow examination: a tertiary care hospital experience","authors":"N. Fareed, T. Mehmood, M. Quraishy, Ghulam Fatima","doi":"10.15406/htij.2021.09.00267","DOIUrl":"https://doi.org/10.15406/htij.2021.09.00267","url":null,"abstract":"ackground: Hematological disorders are quite frequent in all age group. Most of these hematological disorders first present as anemia. Bone Marrow Aspiration plays a major role in the diagnosis of it’s underlying cause. The aim of this study was to analyze the causes of hematological disorders, its spectrum and to interpret the bone marrow aspiration findings. Objective: The aim of the study is to evaluate the clinical profile, spectrum, cytological and histological pattern of various hematological disorders reported in bone marrow aspiration and trephine biopsy respectively. Study design: This was a Retrospective and prospective study. This study was carried out in the Haematology Department of CHK-Central Laboratory from Jan 2018- till date. Methodology: Bone marrow examination of 280 cases of suspected hematological disorders was carried out, who presented to CHK-Central Laboratory for bone marrow Biopsy. Complete detailed history, examination and complete blood counts were recorded. Results: Among 280 cases studied, age of patients ranged from 02 to 75 years with mean age of 38.5 years with male predominance (1.4:1). Most of the patients presented with fever, easy fatigability and generalized weakness. Out of 280 cases of bone marrow biopsy 57 ( 20.3% ) cases showed normal haematopoiesis, while Erythroid Hyperplasia was observed in 10(3.5%) cases and Megaloblastic Anaemia in 05(1.7%) cases. ITP in 15 (5.3%), Hypocellular marrow in 19 (6.7%), Aplastic Anaemia in 24(8.5%) cases. Acute leukemia was seen in 46 cases with 23 (8.2%) cases of ALL and 12(4.2%) cases of AML. CML was seen in 37(13.2%), MPN in 10(3.5)% cases, LPD in 23 (8.2%) cases, Multiple myeloma in 02(0.7%). 01 case (0.3%) of granulomatous pathology and 01 case (0.3%) of Myelodysplastic syndrome were diagnosed exclusively on bone marrow biopsy. Leishmaniasis seen in 1 0.3(%) patient. In addition metastatic deposits of adenocarcinoma were observed in 2(0.7%) cases. Conclusion: The present study showed the usefulness of bone marrow aspiration and trephine biopsy in evaluation of the bone marrow in routine haematological disorders and also for understanding disease progression.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133355596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Appropriate transport of whole blood by drones for cases of massive bleeding 对大出血病例,无人机适当运输全血
Hematology & Transfusion International Journal Pub Date : 2021-10-20 DOI: 10.15406/htij.2021.09.00265
Fumiatsu Yakushiji, Koki Yakushiji, M. Murata, Michiyo Nakahara, Miyuki Teratani, Naoki Hiroi, H. Fujita
{"title":"Appropriate transport of whole blood by drones for cases of massive bleeding","authors":"Fumiatsu Yakushiji, Koki Yakushiji, M. Murata, Michiyo Nakahara, Miyuki Teratani, Naoki Hiroi, H. Fujita","doi":"10.15406/htij.2021.09.00265","DOIUrl":"https://doi.org/10.15406/htij.2021.09.00265","url":null,"abstract":"Background: Whole blood (WB) can be superior to red blood cell (RBC) solutions for transfusion in hemorrhage because it contains coagulation factors and platelets. A previous study reported that the quality of an RBC solution and WB can be maintained during transport by an uncrewed aerial vehicle (drone) at normal temperature. Therefore, we aimed to determine whether this approach could also be used for transport of WB for cases of massive bleeding on the hot and cold days that occur in Japan, by testing this approach twice, on hot and cold days. Method: We used an automobile-transported WB packs obtained by phlebotomy and corresponding segments to a test place in Tomi at a distance of approximately 200 km from Tokyo. Subsequently, a drone (M1000) flight transported the WB and its segments. Results: The influence of the drone flight on WB appeared to be minimal on lactate dehydrogenase (LDH) level, and the WB was confirmed to be problem-free in coagulation tests. Conclusion: We transported WB by the drone and confirmed that there were little hemolysis of the WBs and little reduction in the levels of coagulants.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"158 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115993115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recombinant lectins as pioneering anti-viral agents against COVID-19 重组凝集素作为抗COVID-19的先锋抗病毒药物
Hematology & Transfusion International Journal Pub Date : 2021-08-31 DOI: 10.15406/htij.2021.09.00259
Dr. Ashraf Abdullah Saad
{"title":"Recombinant lectins as pioneering anti-viral agents against COVID-19","authors":"Dr. Ashraf Abdullah Saad","doi":"10.15406/htij.2021.09.00259","DOIUrl":"https://doi.org/10.15406/htij.2021.09.00259","url":null,"abstract":"The primary target for vaccine design and anti-viral therapeutics for the deadly severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) is the coronavirus surface spike (S) glycoprotein. Like other enveloped viruses, S glycoproteins are masked by a dense sugar “coat” of host-derived glycans that mediate immune evasion by molecular mimicry through shielding the immunogenic surface proteins from host immune responses. Paradoxically, this same protective glycan shield can make these sugar-coated viruses vulnerable to immune attack by soluble lectins of the innate immune system that are still able to recognise these glycans as pathogen-associated molecular patterns (PAMPs) leading to complement activation. In reality, recombinant lectins that target virus-associated glycans have the potential to be used as anti-viral agents; and therefore, binding of recombinant lectins to viruses could represent a paradigm shift for viral infection therapy. Likewise, SARS-CoV-2- associated glycans can offer novel targets for recombinant lectins as innovative anti-SARSCoV-2 agents. Unfortunately, pharmacological hurdles currently constrain the entry of recombinant lectins into clinical trials but more vigorous research into potentially useful modifications of these agents can truly develop a new landscape of anti-viral lectin-based therapeutics.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"53 6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122404366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Fever and blood transfusion - Guideline in norm of temperature (in transfusion) 发热和输血。(输血时)体温标准指南
Hematology & Transfusion International Journal Pub Date : 2021-08-31 DOI: 10.15406/htij.2021.09.00260
J. Ginot
{"title":"Fever and blood transfusion - Guideline in norm of temperature (in transfusion)","authors":"J. Ginot","doi":"10.15406/htij.2021.09.00260","DOIUrl":"https://doi.org/10.15406/htij.2021.09.00260","url":null,"abstract":"","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"124 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123032162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overview of myelodysplastic syndrome in Baghdad, Iraq- clinical picture and outcome 伊拉克巴格达骨髓增生异常综合征的概况-临床情况和结果
Hematology & Transfusion International Journal Pub Date : 2021-08-24 DOI: 10.15406/htij.2021.09.00257
Waseem F Al-Tameemi, Sabrin Qasim Ibrahim
{"title":"Overview of myelodysplastic syndrome in Baghdad, Iraq- clinical picture and outcome","authors":"Waseem F Al-Tameemi, Sabrin Qasim Ibrahim","doi":"10.15406/htij.2021.09.00257","DOIUrl":"https://doi.org/10.15406/htij.2021.09.00257","url":null,"abstract":"Background: Myelodysplastic syndromes (MDS) can represent a challenge in diagnosis and treatment because of heterogeneous presentation, unpredictable response to variable measures with propensity for leukemic transformation. Aim of study: To review MDS Iraqi patients in term of presentation, risk stratification and treatment options and to assess outcome of different treatment options in term of response criteria, quality of life and progression. Patients and method: a hospital based study conducted over a period of 21 months from January 2018 till October 2019 in different hematology centers in Baghdad. Any patient with primary or therapy related MDS diagnosed were enrolled in this study. Each patient stratified into different risk groups when applying cytogenetic versus non cytogenetic scoring systems, the therapeutic options for every patient. They observed for their response to different therapeutic modalities and any evidence of progression. Results: Mean age at diagnosis for MDS was 58.7± Anemia was the most common presenting symptom representing 68.4% of patients. MDS with excess blasts-II is forming 28.8%. Majority of patients categorized as intermediate risk group. Hypomethylating agents used for 50% of MDS patients while 32.1% received best available therapy. Those on HMA achieve partial remission in 7.1%, 25.2% reached to stable disease, hematological improvement in 25.2%. Death outcome in 21.6 with a mean survival is 7.7 months. Disease progression in 10.8%, 7.2% showed leukemic transformation. Conclusion: Iraqi MDS patients present at younger age with advanced manifestation that needs standard risk stratification. The non-cytogenetic score systems can't be of equivalent application even low resources circumstances.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133129814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Doxorubicin delivery via novel lyophilized/reconstituted platelet-product has anti-cancer activity 新型冻干/重组血小板产品给药阿霉素具有抗癌活性
Hematology & Transfusion International Journal Pub Date : 2021-05-20 DOI: 10.15406/htij.2021.09.00251
Adrienne M. P. Wright, Ying Yi Zheng, Amber Lee, Braden Ishler, Daniel A Sheik, Keith A Moskowitz, Mark L Weiss
{"title":"Doxorubicin delivery via novel lyophilized/reconstituted platelet-product has anti-cancer activity","authors":"Adrienne M. P. Wright, Ying Yi Zheng, Amber Lee, Braden Ishler, Daniel A Sheik, Keith A Moskowitz, Mark L Weiss","doi":"10.15406/htij.2021.09.00251","DOIUrl":"https://doi.org/10.15406/htij.2021.09.00251","url":null,"abstract":"Background: Cancer is a global health concern with millions of people diagnosed annually. Chemotherapy remains the primary treatment for many cancers despite its toxic side effects. Currently, there is focus on developing nanoparticle systems to enhance the specificity and efficiency of chemotherapeutics. Biological drug delivery methods, e.g., platelets, offer advantages compared to traditional, synthetic nanoparticles and may enhance therapeutic potency by avoiding immune interactions. Platelets are a potential source of biological nanoparticles for drug delivery but, their short shelf-life limits their therapeutic potential. Lyophilization has been used to increase the shelf-life and stability of platelets. Methods: Here, we evaluate a modified version of Cellphire’s proprietary freeze-dried platelet product loaded with the cytotoxic drug, doxorubicin, for delivery to hemangiosarcoma cells. Results: We demonstrate that 1-10% volume/volume (v/v) addition of doxorubicin-loaded Lyophilized Human Platelets (DOX-LHP) to hemangiosarcoma cultures have potent anti-cancer activity by inhibiting proliferation, metabolism, and promoting apoptosis. Further, hemangiosarcoma cells exposed to 5% and 10% v/v DOX-LHP contained 2.2x and 4x more intracellular doxorubicin compared to cells treated with media containing 5 µM free doxorubicin. Conclusions: These results suggest that lyophilized, DOX-LHP overcome the storage limitations of platelets and once reconstituted they function as effective drug delivery vehicles for cytotoxic compounds.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132612176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful allogeneic hematopoietic stem cell transplantation in a child with transfusion-dependent pyridoxine refractory hereditary sideroblastic anaemia 异基因造血干细胞移植治疗输注依赖型吡哆醇难治性遗传性铁母细胞贫血1例成功
Hematology & Transfusion International Journal Pub Date : 2020-01-24 DOI: 10.15406/htij.2020.08.00211
T. Rostami, A. Kiumarsi, Amir Abbas Hedayati Asl, Ashraf Sadat Hoseini,, Asadollah Mousavi
{"title":"Successful allogeneic hematopoietic stem cell transplantation in a child with transfusion-dependent pyridoxine refractory hereditary sideroblastic anaemia","authors":"T. Rostami, A. Kiumarsi, Amir Abbas Hedayati Asl, Ashraf Sadat Hoseini,, Asadollah Mousavi","doi":"10.15406/htij.2020.08.00211","DOIUrl":"https://doi.org/10.15406/htij.2020.08.00211","url":null,"abstract":"We report a case of pyridoxine refractory, hereditary sideroblastic anaemia (HSA) in a 23 months old girl who underwent bone marrow stem cell transplantation (BMSCT) from his 28-year-old HLA‐identical maternal uncle. By using short tandem repeat polymorphism, 95% donor cells were observed in peripheral blood on day +15, +30, +90 and until the present time; the patient did not develop any significant graft‐versus‐host disease or other transplant complications. One year after transplantation, the patient has a Lansky score1 of 100, with a normal cell blood count (CBC).","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"177 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123513771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rickettsioses complicated with dry gangrene and thrombotic thrombocytopenic purpura -a case report 立克次体病合并干性坏疽和血栓性血小板减少性紫癜1例
Hematology & Transfusion International Journal Pub Date : 1900-01-01 DOI: 10.15406/htij.2021.09.00266
Mhd Jayasundara, W. Kularatne
{"title":"Rickettsioses complicated with dry gangrene and thrombotic thrombocytopenic purpura -a case report","authors":"Mhd Jayasundara, W. Kularatne","doi":"10.15406/htij.2021.09.00266","DOIUrl":"https://doi.org/10.15406/htij.2021.09.00266","url":null,"abstract":"Background: Spotted fever group rickettsioses has become more apparent in certain provinces of Sri Lanka. It has a vast diversity in its clinical presentation. However, toe gangrene and thrombotic thrombocytopenic purpura are rare presentations of rickettsioses and are less reported to date. Case presentation: Acute febrile illness of a 28year old Army Officer was complicated with seizures, acute kidney injury, toe gangrene and skin necrosis. He was treated as for spotted fever group rickettsioses complicated with dry gangrene and thrombotic thrombocytopenic purpura. Accurate clinical diagnosis and specific treatment resulted in dramatic recovery leaving behind only the residual gangrenous toes. Conclusion: This case report highlights the importance of accurate clinical diagnosis along with timely intervention to determine the outcome of certain detrimental and rare complications of spotted fever group rickettsioses.","PeriodicalId":103294,"journal":{"name":"Hematology & Transfusion International Journal","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123794431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信